BioNTech BNTX 深 沪
交易中 03-25 11:17:47 美东时间
88.63
+1.820
+2.10%
华盛通- 最 高88.93
- 今 开88.00
- 成交量 13.51万股
- 最 低 87.76
- 昨 收 86.81
- 总市值 222.40亿
- 52周最高 124.00
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 79.52
- 委 比 -86.92%
- 总股本 2.51亿
- 历史最高 462.4502
- 量 比 0.42
- 振 幅 1.35%
- 历史最低 10.9752
- 每 手 1
- 风险率 7.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Trump administration reportedly shortlisting CDC nominees
Two physicians with somewhat contrasting views on vaccines are among the potential candidates the Trump administration is considering as its pick to lead the U.S. Centers for Disease Control and Preve...
03-22 00:24
BioNTech FY 2025 net loss widens 70.83% to EUR 1.14 billion on revenue up 4.33% to EUR 2.87 billion
BioNTech FY 2025 net loss widens 70.83% to EUR 1.14 billion on revenue up 4.33% to EUR 2.87 billion BioNTech published a fourth-quarter and full-year 2025 financial results and corporate update presentation. Full-year revenue was EUR 2.87 billion, up 4.33%. Full-year net loss was EUR 1.14 billion an
03-20 20:58
美股机会日报 | 高盛：一旦伊朗冲突结束，美股将掀起“逼空”狂潮！半导体产业酝酿新一轮涨价潮
高盛：一旦伊朗冲突结束，美股将掀起“逼空”狂潮！半导体产业酝酿新一轮涨价潮，德州仪器、恩智浦等4月集体调价；特斯拉第三代人形机器人亮相>>
03-12 20:12
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Moderna, BioNTech rise as vaccine advisory panel backs off mRNA vaccine threat
Stocks focused on developing mRNA vaccines, including Moderna (MRNA) and BioNTech (BNTX), are higher in Wednesday trading following a report that an HHS vaccines advisory committee is walking back a p...
03-12 03:24
BioNTech Analysts Slash Their Forecasts After Q4 Earnings
BioNTech (BNTX) reported upbeat Q4 results and FY26 sales guidance below estimates. Shares gained 7.7% on Wednesday. Analysts have mixed opinions.
03-11 23:09
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
